Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

ImmunityBio: Clinical Trials & FDA Approval Profile

ImmunityBio (Global / Institutional) sponsors 39 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (6 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)61.5%
Median Closed Enrollment vs National (145 pts)9 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for ImmunityBio
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)39
Active Pipeline (Recruiting Now)14 (6)
Completed vs Stopped Early1 / 24 (61.5%)
Median Closed Actual Enrollment9 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With ImmunityBio
Hospital Research SiteLocationShared Protocols
Washington University and Siteman Cancer CenterSaint Louis, MO4
Medical University of South CarolinaCharleston, SC3
Hoag Memorial Hospital PresbyterianNewport Beach, CA3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by ImmunityBio
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06745908Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in ParticipPhase IIIRECRUITING
NCT03228667QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsPhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the ImmunityBio Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI